drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous TCR-T)
drug_description
Autologous, gene-modified TCR-engineered T cells (TCR-T; T-Plex) expressing a high-affinity TCR specific for PRAME peptide presented by HLA-A*02:01; engages peptide–HLA on tumor cells to activate TCR/CD3 signaling and cytotoxicity post-lymphodepletion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Transgenic
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a high-affinity TCR specific for the PRAME peptide presented by HLA-A*02:01. Upon binding the peptide–HLA complex on tumor cells, the engineered TCR engages CD3 to trigger TCR signaling, leading to T-cell activation, cytokine release, and cytotoxic killing of PRAME-expressing, HLA-A*02:01–positive cancer cells after lymphodepletion.
drug_name
TSC-203-A0201
nct_id_drug_ref
NCT05973487